{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:17Z","timestamp":1794047417106,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Here we present the 3-year results of ZUMA-4, a phase I\/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in pediatric\/adolescent patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Phase I explored two dose levels and formulations. The primary endpoint was the incidence of dose-limiting toxicities. Thirty-one patients were enrolled; KTE-X19 was administered to 24 patients (median age 13.5 years, range 3-20; median follow-up 36.1 months). No dose-limiting toxicities were observed. All treated patients had grade \u22653 adverse events, commonly hypotension (50%) and anemia (42%). Grade 3 cytokine release syndrome rates were 33% in all treated patients, 75% in patients given the dose of 2\u00d7106 CAR T cells\/kg, 27% in patients given the dose of 1\u00d7106 cells\/kg in the 68 mL formulation, and 22% in patients given the dose of 1\u00d7106 cells\/kg in the 40 mL formulation; the percentages of patients experiencing grade \u22653 neurologic events were 21%, 25%, 27%, and 11% respectively. Overall complete remission rates (including complete remission with incomplete hematologic recovery) were 67% in all treated patients, 75% in patients given 2\u00d7106 CAR T cells\/kg, 64% in patients given 1\u00d7106 cells\/kg in the 68 mL formulation, and 67% in patients given 1\u00d7106 cells\/kg in the 40 mL formulation. Overall minimal residual diseasenegativity rates were 100% among responders; 88% of responders underwent subsequent allogeneic stem-cell transplantation. In the 1\u00d7106 (40 mL) group (recommended phase II dose), the median duration of remission censored at allogeneic stem-cell transplantation and median overall survival were not reached. Pediatric\/adolescent patients with relapsed\/refractory B-cell acute lymphoblastic leukemia achieved high minimal residual disease-negative remission rates with a manageable safety profile after a single dose of KTE-X19. Phase II of the study is ongoing at the dose of 1\u00d7106 CAR T cells\/kg in the 40 mL formulation. ClinicalTrials.gov: NCT02625480.<\/jats:p>","DOI":"10.3324\/haematol.2022.280678","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:02:32Z","timestamp":1666242152000},"page":"747-760","source":"Crossref","is-referenced-by-count":44,"title":["Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Alan S.","family":"Wayne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayne H.","family":"Rouce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Dela","family":"Ziga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra C.","family":"Schuberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovely","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remus","family":"Vezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad Kharabi","family":"Masouleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"45403","doi-asserted-by":"crossref","unstructured":"DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2018; 24(6):453-467.","DOI":"10.1177\/1078155217713363"},{"key":"45404","doi-asserted-by":"crossref","unstructured":"Sun W, Malvar J, Sposto R. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia &amp; Lymphoma study. Leukemia. 2018; 32(11):2316-2325.","DOI":"10.1038\/s41375-018-0094-0"},{"key":"45405","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"45406","doi-asserted-by":"crossref","unstructured":"Crotta A, Zhang J, Keir C. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Curr Med Res Opin. 2018; 34(3):435-440.","DOI":"10.1080\/03007995.2017.1384373"},{"key":"45407","doi-asserted-by":"crossref","unstructured":"Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am. 2015; 62(1):61-73.","DOI":"10.1016\/j.pcl.2014.09.006"},{"key":"45408","doi-asserted-by":"crossref","unstructured":"Gaynon PS, Qu RP, Chappell RJ. Survival after relapse in childhood acute lymphoblastic leukemia. Cancer. 1998; 82(7):1387-1395.","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1"},{"key":"45409","doi-asserted-by":"crossref","unstructured":"Malempati S, Gaynon PS, Sather H, La MK Stork LC, Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007; 25(36):5800-5807.","DOI":"10.1200\/JCO.2007.10.7508"},{"key":"45410","doi-asserted-by":"crossref","unstructured":"Nguyen K, Devidas M, Cheng SC. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008; 22(12):2142-2150.","DOI":"10.1038\/leu.2008.251"},{"key":"45411","doi-asserted-by":"crossref","unstructured":"Gassas A, Sung L, Saunders EF, Doyle J. Graft-versus-leukemia effect in hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia: significantly lower relapse rate in unrelated transplantations. Bone Marrow Transplant. 2007; 40(10):951-955.","DOI":"10.1038\/sj.bmt.1705853"},{"key":"45412","doi-asserted-by":"crossref","unstructured":"Kato M, Horikoshi Y, Okamoto Y. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant. 2012; 47(10):1307-1311.","DOI":"10.1038\/bmt.2012.29"},{"key":"45413","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zecca M, Messina C. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002; 16(11):2228-2237.","DOI":"10.1038\/sj.leu.2402690"},{"key":"45414","doi-asserted-by":"crossref","unstructured":"Bader P, Salzmann-Manrique E, Balduzzi A. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 2019; 3(21):3393-3405.","DOI":"10.1182\/bloodadvances.2019000449"},{"key":"45415","doi-asserted-by":"crossref","unstructured":"Pulsipher MA, Carlson C, Langholz B. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. Blood. 2015; 125(22):3501-3508.","DOI":"10.1182\/blood-2014-12-615757"},{"key":"45416","doi-asserted-by":"crossref","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016; 34(36):4381-4389.","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"45417","unstructured":"BLINCYTO (blinatumomab) [package insert]. 2022."},{"key":"45418","unstructured":"BLINCYTO (blinatumomab) [Summary of Product Characteristics]. 2022."},{"key":"45419","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Mergen N. Blinatumomab in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022; 6(3):1004-1014.","DOI":"10.1182\/bloodadvances.2021005579"},{"key":"45420","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zugmaier G, Mergen N. Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J. 2020; 10(7):77.","DOI":"10.1038\/s41408-020-00342-x"},{"key":"45421","unstructured":"KYMRIAH (tisagenlecleucel ) [Summary of Product Characteristics]. 2022."},{"key":"45422","unstructured":"KYMRIAH (tisagenlecleucel) [package insert]. 2022."},{"key":"45423","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"45424","doi-asserted-by":"crossref","unstructured":"Rives S, Maude SL, Hiramatsu H. Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study. Hemasphere. 2022; 6(Suppl 3):27-28.","DOI":"10.1097\/01.HS9.0000843344.19780.98"},{"key":"45425","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702.","DOI":"10.1097\/CJI.0b013e3181ac6138"},{"key":"45426","doi-asserted-by":"crossref","unstructured":"Kochenderfer JN, Wilson WH, Janik JE. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-4102.","DOI":"10.1182\/blood-2010-04-281931"},{"key":"45427","doi-asserted-by":"crossref","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-528.","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"45428","unstructured":"TECARTUS\u00ae (brexucabtagene autoleucel) [prescribing information]. 2021."},{"key":"45429","unstructured":"TECARTUS\u00ae (autologous anti-CD19-transduced CD3+ cells) [Summary of Product Characteristics]. 2021."},{"key":"45430","doi-asserted-by":"crossref","unstructured":"Shah BD, Ghobadi A, Oluwole OO. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502.","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"45431","doi-asserted-by":"crossref","unstructured":"Sabatino M, Choi K, Chiruvolu V, Better M. Production of anti-CD19 CAR T cells for ZUMA-3 and -4: phase 1\/2 multicenter studies evaluating KTE-C19 in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (R\/R ALL). Blood. 2016; 128(22):1227.","DOI":"10.1182\/blood.V128.22.1227.1227"},{"key":"45432","doi-asserted-by":"crossref","unstructured":"Shah BD, Bishop MR, Oluwole OO. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021; 138(1):11-22.","DOI":"10.1182\/blood.2020009098"},{"key":"45433","doi-asserted-by":"crossref","unstructured":"Wayne AS, Michel G, Lee DW. ZUMA-4: A phase 1\/2 multicenter study of KTE-X19 in pediatric and adolescent patients with relapsed\/refractory B cell acute lymphoblastic leukemia or non-Hodgkin lymphoma. Blood. 2020; 136(Suppl 1):42.","DOI":"10.1182\/blood-2020-137233"},{"key":"45434","doi-asserted-by":"crossref","unstructured":"Lee DW, Gardner R, Porter DL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"45435","doi-asserted-by":"crossref","unstructured":"Park JH, Riviere I, Gonen M. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018; 378(5):449-459.","DOI":"10.1056\/NEJMoa1709919"},{"key":"45436","doi-asserted-by":"crossref","unstructured":"Hay KA, Gauthier J, Hirayama AV. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019; 133(15):1652-1663.","DOI":"10.1182\/blood-2018-11-883710"},{"key":"45437","doi-asserted-by":"crossref","unstructured":"Summers C, Wu QV, Annesley C. Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage. Transplant Cell Ther. 2022; 28(1):21-29.","DOI":"10.1016\/j.jtct.2021.10.003"},{"key":"45438","doi-asserted-by":"crossref","unstructured":"Shah NN, Lee DW, Yates B. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021; 39(15):1650-1659.","DOI":"10.1200\/JCO.20.02262"},{"key":"45439","doi-asserted-by":"crossref","unstructured":"Fabrizio VA, Kernan NA, Boulad F. Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020; 55(11):2160-2169.","DOI":"10.1038\/s41409-020-0926-1"},{"key":"45440","doi-asserted-by":"crossref","unstructured":"Grupp SA, Maude SL, Rives S. Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia. Blood. 2018; 132(Suppl 1):895.","DOI":"10.1182\/blood-2018-99-112599"},{"key":"45441","doi-asserted-by":"crossref","unstructured":"Pasquini MC, Hu ZH, Curran K. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020; 4(21):5414-5424.","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"45442","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9):836-847.","DOI":"10.1056\/NEJMoa1609783"},{"key":"45443","doi-asserted-by":"crossref","unstructured":"Gardner RA, Finney O, Annesley C. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331.","DOI":"10.1182\/blood-2017-02-769208"},{"key":"45444","doi-asserted-by":"crossref","unstructured":"Myers RM, Taraseviciute A, Steinberg SM. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022; 40(9):932-944.","DOI":"10.1200\/JCO.21.01405"},{"key":"45445","doi-asserted-by":"crossref","unstructured":"Pillai V, Muralidharan K, Meng W. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019; 3(22):3539-3549.","DOI":"10.1182\/bloodadvances.2019000692"},{"key":"45446","doi-asserted-by":"crossref","unstructured":"Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2019; 16:136-144.","DOI":"10.1016\/j.omtm.2019.11.018"},{"key":"45447","doi-asserted-by":"crossref","unstructured":"Xu Y, Zhang M, Ramos CA. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014; 123(24):3750-3759.","DOI":"10.1182\/blood-2014-01-552174"},{"key":"45448","doi-asserted-by":"crossref","unstructured":"Rheingold SR, Ji L, Xu X. Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children\u2019s Oncology Group (COG) study. J Clin Oncol. 2019; 37(15_suppl):10008.","DOI":"10.1200\/JCO.2019.37.15_suppl.10008"},{"key":"45449","doi-asserted-by":"crossref","unstructured":"Oskarsson T, S\u00f6derh\u00e4ll S, Arvidson J. Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome. Haematologica. 2016; 101(1):68-76.","DOI":"10.3324\/haematol.2015.131680"},{"key":"45450","doi-asserted-by":"crossref","unstructured":"Schrappe M, Hunger SP, Pui CH. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012; 366(15):1371-1381.","DOI":"10.1056\/NEJMoa1110169"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280678\/74940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.280678\/75378","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10837\/74940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:37Z","timestamp":1794045757000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.280678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.280678","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}